CT CURE

COVID-19 pandemic was the first one in history when humans have been able to fight against. Therapeutics –vaccines and also treatments- were the key issue in achieving it. They helped to save lives, speed up recovery time and help to avoid or reduce periods of hospitalization. With the aim of improving the availability, accessibility and affordability of medicines and medical devices as well as relevant products in case of health crises and supporting innovation for such products, in 2022, the EU launched the CT Cure joint action as part of the EU4Health Programme. This project was then born with a very concrete and strategic role: to provide a harmonised and accelerated assessment of multinational clinical trial applications with COVID-19 therapeutics using the Clinical Trials Information System (CTIS) for 24 months. Nowadays, the situation around this disease has evolved significantly and, as a result, the project has expanded its scope to therapies that bridge the gap between therapeutic and preventive treatments in order to include as many clinical trials as possible and make the European Union a more attractive region for large, multi-country trials using master protocols. This joint action will also work to face possible public health crisis in the best, the fairest and the fastest way:

• Motivating sponsors to seek for previous scientific advice.
• Encouraging participation in the horizon scanning for detecting pro-actively promising therapeutic candidates.
• Allowing all European citizens to get better treatments.
• Contributing to the creation of a favorable environment for innovation, research and development for medicines.

More information can be found on web side https://ctcure.eu/